MDD
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
VigonvitaLV232 40mg
NeuroneticsTranscranial Magnetic Stimulation
Clinical Trials (2)
Total enrollment: 7,690 patients across 2 trials
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
Start: Apr 2025Est. completion: Dec 2026
Phase 2Recruiting
A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents
Start: May 2023Est. completion: May 20237,690 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 7,690 patients
2 companies competing in this space